Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.
Hepatology
; 67(2): 791-793, 2018 02.
Article
en En
| MEDLINE
| ID: mdl-28921620
ABSTRACT
Direct-acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV-HCV-coinfected patients treated with DAAs. We report on a case of late HBV reactivation after DAA-based treatment of recurrent hepatitis C in an antibody against hepatitis B core antigen (anti-HBc)-positive LT recipient. (Hepatology 2018;67791-793).
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Antivirales
/
Activación Viral
/
Virus de la Hepatitis B
/
Trasplante de Hígado
/
Hepatitis C Crónica
/
Anticuerpos contra la Hepatitis B
/
Antígenos del Núcleo de la Hepatitis B
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Hepatology
Año:
2018
Tipo del documento:
Article
País de afiliación:
Suiza